NCT02159495 - Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

August 6, 2026

Study Completion Date

August 6, 2026

Conditions

Adult Acute Myeloid Leukemia in RemissionAcute Biphenotypic LeukemiaEarly Relapse of Acute Myeloid LeukemiaLate Relapse of Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmAcute Myeloid LeukemiaAdult Acute Lymphoblastic LeukemiaInterleukin-3 Receptor Subunit Alpha PositiveMinimal Residual DiseaseRefractory Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

BIOLOGICAL

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes

Given IV

DRUG

Fludarabine Phosphate

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte